Three pharmaceutical enterprises withdraw from the market, and the life of Chinese herbal medicine enterprises becomes more and more difficult

[industry trends of pharmaceutical network] on September 2, Shaanxi pharmaceutical regulatory bureau issued a notice, according to the independent application of the enterprise, agreeing to cancel the drug business license of Yan'an Xin'an Pharmaceutical Co., Ltd numbered as Shaanxi aa9110004 According to the public information, Xin'an pharmaceutical was established on November 24, 2004, and the licensed business items include proprietary Chinese medicine, chemical pharmaceutical preparations, antibiotics, etc The company's business direction has changed in recent years, and it tends to hold or independently operate medical institutions and drug retail enterprises At present, there are 4 private hospitals, 4 pharmacies and 3 clinics On the same day, Sichuan Provincial Food and Drug Administration issued a notice saying that Sichuan Yihe Pharmaceutical Co., Ltd applied for the termination of drug production, and now the company's drug production license and GMP certificate numbered Sichuan 20160359 are cancelled according to law The notice also shows that if no unit or individual raises an objection within 10 working days from the date of this announcement, the company's drug production license and GMP certificate will be officially cancelled, and the original of the certificate will be handed over by Sichuan food and Drug Administration for cancellation According to the public information, Yihe Pharmaceutical Co., Ltd is a GMP certified Chinese Herbal Pieces processing enterprise integrating traditional Chinese Herbal Pieces processing and processing technology with modern pharmaceutical technology Its production scope includes Chinese herbal pieces, etc According to the 6th pharmaceutical quality announcement of Chongqing food and Drug Administration in 2017, the pharmaceutical enterprise is also listed in the list of unqualified drugs in the random inspection On September 3, Guizhou drug administration announced the announcement of cancellation of drug production scope and GMP certificate issued by Guizhou drug administration No 3 in 2019 Guizhou Tongjitang traditional Chinese medicine decoction pieces Co., Ltd took the initiative to apply for cancellation of the scope of drug production Due to the termination of the plant leasing contract, the enterprise no longer conducts drug production in the workshop after the termination of the contract After examination, Guizhou food and Drug Administration decided to cancel the drug production scope and GMP certificate of the enterprise according to law According to the public information, the business scope of Guizhou Tongjitang Herbal Pieces Co., Ltd is to produce and sell herbal pieces Chinese herbal pieces is an important part of Chinese medicine, which is related to the safety of the people's medication However, the quality of Chinese herbal pieces is uneven, which has become a "serious disaster area", so it is urgent to strengthen the management In recent years, the drug regulatory authorities have continued to increase the supervision, inspection and sampling of Chinese herbal pieces, investigate and expose illegal enterprises and unqualified products in accordance with the law Although the overall quality of Chinese herbal pieces has improved, the non-compliance of enterprises still exists In order to further strengthen the supervision and management of Chinese herbal pieces and improve the quality of Chinese herbal pieces, on August 28, 2018, the State Food and Drug Administration formulated the work plan for centralized treatment of the quality of Chinese herbal pieces, severely cracking down on the production of Chinese Herbal Pieces adulterated with fake, dyed and rotten Chinese herbal medicines The work will be carried out nationwide for one year Local action is also taking place In the middle of August this year, the special inspection and treatment of 2019 concentrated quality improvement (production link) of Chinese Herbal Pieces reported by Fujian food and drug administration showed that from April to July 2019, 31 production enterprises of Chinese herbal pieces were ordered to rectify due to defects, among which 15 pharmaceutical enterprises failed to pass the sampling inspection of 15 batches of Chinese herbal pieces, and one was withdrawn GMP certificate According to the industry, with more and more strict supervision, it is more and more difficult for Chinese herbal medicine enterprises to survive in recent years In 2019, the national and local efforts to improve the quality of Chinese herbal pieces are trumpeting, frequent flight inspections are coming, and the life of Chinese Herbal Pieces enterprises is becoming more and more difficult However, from another point of view, with the continuous improvement of industry concentration, the quality level of Chinese herbal pieces will be further improved in the future.